Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.30 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16480417 | 0.80 | L3MBTL1 (0.37) | CYP2D6CHRNA7CNR2SRD5A1NOTUM | |
| SCHEMBL9893008 | 0.77 | NOTUM (0.35) | CYP2D6CHRNA7CNR2SRD5A1NOTUM | |
| SCHEMBL9107566 | 0.73 | MMP8 (0.43) | CYP2D6CHRNA7CNR2L3MBTL1 | |
| SCHEMBL9110142 | 0.73 | MMP8 (0.43) | CYP2D6CHRNA7CNR2L3MBTL1 | |
| SCHEMBL9891736 | 0.70 | ALDH1A1 (0.41) | SRD5A1NOTUMPTGER3PTGER2 | |
| SCHEMBL9891746 | 0.68 | CNR2 (0.45) | CNR2PTGER3PTGER2 | |
| SCHEMBL9891750 | 0.68 | NOTUM (0.50) | SRD5A1NOTUM | |
| SCHEMBL9891743 | 0.66 | PTGER2 (0.36) | CNR2L3MBTL1PTGER3PTGER2 | |
| SCHEMBL16253054 | 0.66 | CNR2 (0.47) | CNR2SRD5A1 | |
| SCHEMBL9891747 | 0.66 | CNR2 (0.47) | CNR2SRD5A1NOTUML3MBTL1PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CYP2D6 1472/4885CHRNA7 321/4885CNR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.